Skip to content

Effects of Preimplantation Genetic Screening 2.0 on the Clinical Outcomes of Assisted Reproductive Treatment in Patients With Recurrent Pregnancy Loss : A Multi-center-based Prospective Randomized Clinical Trial

Effects of Preimplantation Genetic Screening 2.0 on the Clinical Outcomes of Assisted Reproductive Treatment in Patients With Recurrent Pregnancy Loss : A Multi-center-based Prospective Randomized Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17011921
Enrollment
Unknown
Registered
2017-07-10
Start date
2017-09-30
Completion date
Unknown
Last updated
2017-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unexplained recurrent pregnancy loss

Interventions

PGS group:IVF/ICSI+PGS 2.0
Control group:IVF/ICSI

Sponsors

Shanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 48 Years

Inclusion criteria

Inclusion criteria: 1. regular menstrual cycles and normal level of E2, P, FSH, LH, T,RPL in the early follicular phase; 2. BMI 18.50-24.90 3. no history of poison contact; 4. normal uterine and adnexal ultrasonography; 5. TORCH(-), chlamydia(-), mycoplasma(-), normal leucorrhoea routine, anti-phospholipid antibody (-), antinuclear antibody(-); 6. for the couple, no blood type incompatibility or ABO antibody IgG=164 and normal blood chromosome analysis

Exclusion criteria

Exclusion criteria: 1. hydrosalpinx without operation; endometriosis; polycystic ovary syndrome; adenomyosis; uterine leiomyomata(submucous myoma or non-submucous myoma which size was exceed 4cm and/or with the compressed endometrium);uterine cavity lesions(such as uterine malformation, intrauterine adhesions, the septate uterus, endometritis etc); 2. the former abortion is because of luteal phase defect without treatment; 3. FSH=12IU/L or AMH=1.2ng/ml; 4. thyroid dysfunction or increased CA125 level; 5. acute inflammation of genitourinary system or STD carriers; 6. unable to comply with the study procedures.

Design outcomes

Primary

MeasureTime frame
Ongoing pregnancy;

Secondary

MeasureTime frame
Embryo implantation;Clinical pregnancy;Time to pregnancy;

Countries

China

Contacts

Public ContactSUN XIAOXI

ShangHai Ji Ai Genetics & IVF Institute

xiaoxi_sun@aliyun.com+86 021 63456043

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026